Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 178 Lung Neoplasms 56 Neoplasms 14 NSCLC 11 Brain Neoplasms 11 Neoplasm Metastasis 10 Carcinoma 9 Meningeal Carcinomatosis 6 Colorectal Neoplasms 5 Bronchial Neoplasms 5 Thoracic Neoplasms 4 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Lung Diseases 3 Carcinoma, Squamous Cell 3 Breast Neoplasms 3 Adenocarcinoma of Lung 3 Adenocarcinoma 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumor 2 Prostatic Neoplasms 2 Noonan Syndrome 2 Non Small Cell Lung Cancer Metastatic 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × osimertinib × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡